Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-07
DOI
10.3389/fimmu.2021.795574
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis
- (2021) Jingyi Tong et al. NEUROLOGICAL SCIENCES
- Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
- (2021) Tamara Pérez-Jeldres et al. DRUGS
- Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Xin Wu et al. Frontiers in Pharmacology
- Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis
- (2021) Amirreza Naseri et al. Multiple Sclerosis and Related Disorders
- First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
- (2021) Aurora Zanghì et al. EUROPEAN JOURNAL OF NEUROLOGY
- Cognition and disease characteristics in adult onset versus late onset multiple sclerosis
- (2021) Rachel Butler Pagnotti et al. Multiple Sclerosis Journal
- Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
- (2020) Elyse Swallow et al. Journal of Comparative Effectiveness Research
- Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
- (2020) Oliver Findling et al. Journal of Clinical Medicine
- A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
- (2020) Volker Limmroth et al. Frontiers in Neurology
- Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
- (2020) Helmut Butzkueven et al. BMJ Open
- Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
- (2020) Bruce A. C. Cree et al. JAMA Neurology
- Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,679 patients from 53 studies
- (2020) Zhi-Chun Gu et al. Cardiovascular Diagnosis and Therapy
- Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
- (2020) Jerold Chun et al. DRUGS
- Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis
- (2019) Zhi-Chun Gu et al. Clinical Gastroenterology and Hepatology
- Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
- (2019) Pierre-Eric Juif et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
- (2019) Claudia Volpi et al. Expert Opinion on Drug Discovery
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta‐analysis
- (2019) Ting Yang et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Late onset and young onset relapsing remitting multiple sclerosis. Evidence from a retrospective long-term follow-up study
- (2018) Emanuele D'Amico et al. EUROPEAN JOURNAL OF NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Course of Multiple Sclerosis
- (2018) Sylvia Klineova et al. Cold Spring Harbor Perspectives in Medicine
- A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future
- (2018) Mehrdad Gholamzad et al. INFLAMMATION RESEARCH
- Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
- (2017) Jonathan Q. Tran et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
- (2017) Giancarlo Comi et al. JOURNAL OF NEUROLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
- (2016) Alice Laroni et al. NEUROLOGICAL SCIENCES
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
- (2015) Sonja Krösser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study
- (2015) Damiano Paolicelli et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis
- (2014) Yara Dadalti Fragoso et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications
- (2014) Emilio Vanoli et al. CNS Neuroscience & Therapeutics
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
- (2014) Edward Fox et al. Multiple Sclerosis and Related Disorders
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Modulators of the Sphingosine 1-phosphate receptor 1
- (2013) Mariangela Urbano et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
- (2013) Ralf Gold et al. JOURNAL OF NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Early tolerability and safety of fingolimod in clinical practice
- (2012) Daniel Ontaneda et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
- (2012) T Saida et al. Multiple Sclerosis Journal
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started